KC
NAUT icon

Kepos Capital’s Nautilus Biotechnolgy NAUT Stock Holding History

Kepos Capital’s Portfolio NAUT Stock Details NAUT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-600
Closed -$6K – 356
2020
Q3 		$6K Buy
+600
New +$6.4K ﹤0.01% 271

Other funds holding NAUT

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlueCrest Capital Management
BlueCrest Capital Management St Helier, Jersey $3.04B AUM 26.78% 1-Year Est. Return
Nantahala Capital Management
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
GL
Governors Lane New York $1.2B AUM 26.21% 1-Year Est. Return
SRCM
Sage Rock Capital Management New York $22.3M AUM 4.09% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Kepos Capital's NAUT Position: Q4 2020 in Review

Kepos Capital sold out of Nautilus Biotechnolgy (NAUT) in Q4 2020, closing a stake of 600 shares — an estimated $6K sold.

Kepos Capital first reported a position in NAUT in Q3 2020 and held it in 1 quarter. The position peaked at $6K in Q3 2020. 43 funds tracked by Wall St. Rank hold NAUT as of Q4 2020.

  • Kepos Capital reported no remaining Nautilus Biotechnolgy position as of Q4 2020 after selling out during the quarter.
  • Kepos Capital sold 600 Nautilus Biotechnolgy shares in Q4 2020, an estimated $6K.
  • Kepos Capital first reported a position in Nautilus Biotechnolgy in Q3 2020 and held it in 1 quarter.
  • Kepos Capital's Nautilus Biotechnolgy position peaked at $6K in Q3 2020.
  • 43 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q4 2020.

Based on Kepos Capital's 13F filing for Q4 2020, filed 12 Feb 2021.